AstraZeneca Pharma India Limited is a subsidiary of the global biopharmaceutical company AstraZeneca, which has been operating in India for over 40 years. The company focuses on discovering, developing, manufacturing and marketing prescription medicines that improve and extend people’s lives.

The company's product portfolio spans across several therapeutic areas including oncology, cardiovascular, respiratory, inflammation and autoimmune diseases. Some of its well-known drugs include Osimertinib (Tagrisso) for non-small cell lung cancer, Durvalumab (Imfinzi) for advanced bladder cancer, and Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.

One aspect that sets AstraZeneca apart from its competitors is its commitment to innovation. The company invests heavily in research and development with an aim to bring forth groundbreaking treatments that address unmet medical needs. It leverages innovative technologies such as genomics, big data analytics and artificial intelligence to drive drug discovery and development processes.

In addition to its focus on cutting-edge science and medicine, AstraZeneca also stands out due to its dedication to sustainability initiatives aimed at reducing environmental impact throughout their operations. This includes efforts towards carbon neutrality across their entire value chain by 2025.

A notable collaboration worth mentioning is the partnership between AstraZeneca Pharma India Limited and the Indian government's Department of Biotechnology where they have jointly established a Centre of Excellence focused on researching potential COVID-19 vaccines as part of India's fight against the pandemic.